Loyal Valley Capital

Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China.

Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China.

Beijing Surgerii Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive surgical robot systems in China. Founded in 2014 and based in Beijing, the company focuses on innovative technologies, particularly the next generation of flexible continuum robotic arms. Surgerii Technology aims to transform clinical practices through its single-hole and porous laparoscopic robot systems, enhancing the standard of care in minimally invasive surgeries. With a commitment to independent research and development, the company leverages its expertise in system design and integration to advance the medical equipment industry in China.

MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.

Leads Biolabs is a biotechnology company focused on developing innovative antibody-based therapeutics to address unmet medical needs in oncology and immunological diseases. Founded in 2014 and headquartered in China, the company has established a strong research and development pipeline featuring over ten projects centered on monoclonal and bispecific antibodies for cancer immunotherapy. By concentrating on tumor immunotherapy, Leads Biolabs aims to enhance treatment outcomes and access for patients globally, thereby improving their medical conditions and overall quality of life.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to address unmet clinical needs in the treatment of ophthalmic diseases. The company boasts a portfolio of breakthrough technologies aimed at providing effective solutions for patients with rare eye conditions. Founded by prominent life sciences investors, Arctic Vision is led by an experienced team of industry veterans skilled in research and development as well as the commercialization of eye care products. Its commitment to advancing ophthalmic medicine positions it as a key player in both the Asian and global markets.

MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.

CARsgen Therapeutics, Ltd. is a clinical-stage immunotherapy company based in Shanghai, China, focused on developing chimeric antigen receptor T-cell (CAR-T) therapeutics for various cancers, including liver, lung, stomach, and brain cancers. The company specializes in CAR-T technology that enables T cells to target and destroy cancer cells by recognizing specific cell surface proteins. Notably, CARsgen’s therapies are designed to treat late-stage hepatocellular carcinoma (HCC) and lung squamous cell carcinoma. The company has also made significant advancements in clinical trials, having completed the world's first dose-ascending injection tests for HCC and exclusive tests for glioblastoma multiforme (GBM) in China. CARsgen collaborates with institutions such as the Shanghai Cancer Institute and Shanghai Renji Hospital, and is supported by prominent venture capital funding, positioning it to introduce innovative cancer treatments both in China and globally.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Hygeia Healthcare Group is a leading oncology-focused healthcare group in China. The company operates its own hospitals, provides third-party radiotherapy service, and manages partner hospitals. Its core business consists of 7 oncology hospitals and 3 managed hospitals in in 6 provinces in China. In addition, the company provides services to 15 hospital partners (including managed hospitals) in 9 provinces of China on its radiotherapy centers.

Pop Mart International Group Ltd is a Chinese company specializing in the design, development, and retail of designer toys, particularly in the pop culture sector. The company has established a comprehensive operational platform that encompasses the entire industry chain of these collectibles. Pop Mart's products are marketed in various regions, including Mainland China, Hong Kong, Macao, Taiwan, and other international markets. The majority of its revenue is derived from retail sales through physical stores, complemented by sales from roboshops, wholesale distribution, and online platforms. Pop Mart is organized into two main segments: operations in Mainland China and operations in Hong Kong, Macao, Taiwan, and overseas markets.

Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.

Perfect Diary is an e-commerce-based cosmetic brand. The company is committed to exploring the trends in international cosmetics and the frontiers of fashion to provide easy-to-use cosmetics products for young Asian women.Perfect Diary is professional in branding and online traffic management. By launching co-branded cosmetic products with KOLs, idols and even some famous organizations like the British Museum

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

RemeGen, Ltd. is a biopharmaceutical company based in Yantai, Shandong Province, China, focused on addressing unmet medical needs for patients with life-threatening conditions. The company specializes in the research, development, manufacturing, and commercialization of innovative biologics, particularly monoclonal antibodies and antibody-drug conjugates. RemeGen's leading products include Telitacicept, aimed at treating systemic lupus erythematosus, and Disitamab Vedotin, designed for various cancers. The company’s therapeutic offerings target significant health issues, including autoimmune diseases, oncology, and ophthalmology. With operations in both China and the United States, RemeGen primarily generates its revenue from the Chinese market.

Akeso Biopharma, based in Zhongshan, China, operates as a contract research organization (CRO) specializing in the discovery and development of antibody and protein drugs. Founded in 2012, the company provides comprehensive CRO services to both domestic and international pharmaceutical clients, focusing on areas such as protein expression, antibody generation, assay development, and humanization. Akeso has developed an extensive biopharmaceutical research and development platform, with a robust product pipeline that includes over 30 drugs targeting cancers, autoimmune diseases, inflammation, and cardiovascular conditions. Among these, 17 drugs have progressed to clinical stages, including two first-in-class bi-specific antibody drugs. The company collaborates with various pharmaceutical firms to innovate and develop new drug candidates, establishing itself as a leader in the industry through its advanced facilities and expertise.

Mahua Fun Age, the largest drama agency in China, was founded in 2003 and has produced popular dramas and movies such as "Clown Loves Beauty", "Count of Mountain Wulong", "Dream of those Years", "Xialuo’s trouble", and "Donkey water". With a strong portfolio of over 20 high-quality original shows and intellectual properties, Mahua Fun Age has established a significant presence in the entertainment industry. In 2016 alone, the company organized more than 1,600 tour shows across China, showcasing its creativity and appeal to a wide audience.

NetEase Cloud Music, established in 2013 and based in Hangzhou, China, specializes in online music streaming services through its mobile application. The platform enables users to access a wide variety of music and offers additional features, such as music discovery and social networking capabilities. As a subsidiary of NetEase, Inc., NetEase Cloud Music has grown to become a significant player in the Chinese music streaming market, catering to the evolving preferences of its audience while developing applications for smartphones to enhance user experience.

EVE Energy Co., Ltd. is a leading manufacturer of lithium batteries based in Huizhou, China, established in 2001. The company specializes in the development and production of a wide range of lithium primary and lithium-ion batteries, including lithium thionyl chloride and lithium-manganese dioxide batteries. EVE Energy's products serve various applications, such as smart meters, intelligent security systems, and new energy vehicles. The company also provides advanced power systems for electric vehicles and energy storage solutions for residential and industrial use. As a national high-tech enterprise, EVE has made significant investments in battery technology and innovation, positioning itself as a global frontrunner in the lithium thionyl chloride battery market. With a commitment to high-quality manufacturing and service, EVE Energy continues to expand its presence in China, Hong Kong, Taiwan, the United States, and Europe.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

InnoCare is a biopharmaceutical company based in China, focused on discovering, developing, and commercializing innovative treatments for cancer and autoimmune diseases. The company boasts a skilled scientific team with extensive experience in drug innovation from both the U.S. and China, supported by an accomplished Scientific Advisory Board comprised of experts from prominent universities, hospitals, and the pharmaceutical sector. InnoCare's product pipeline includes several key therapies, such as orelabrutinib, ibrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune disorders. The company is also dedicated to addressing autoimmune diseases linked to abnormal B-cell or T-cell functions, positioning itself as a leader in advancing medical treatments and tackling complex health challenges.

Linklogis Inc is a technology solution provider specializing in supply chain finance in China. The company develops a financial service platform that leverages big data, artificial intelligence, and blockchain technologies to facilitate direct connections between asset providers and funding sources. This enables small-sized companies to access financing more conveniently. Linklogis operates in two primary segments: Supply Chain Finance Technology Solutions and Emerging Solutions. The Supply Chain Finance Technology Solutions encompass products like Anchor Cloud and FI Cloud, while Emerging Solutions include offerings such as Crossborder Cloud and SME credit technology solutions. By focusing on practical applications and innovative technologies, Linklogis aims to enhance the efficiency of supply chain financial services in the market.

Teligene Ltd. is a pharmaceutical research and development company based in Jiangsu, China, established in 2011. The company specializes in the development of small-molecule drugs, particularly innovative treatments for oncology. Teligene's focus is on the research, development, and industrialization of small molecule targeted anti-tumor drugs, utilizing advanced drug development technologies. The experienced management team is well-versed in contemporary trends and practices in drug development both domestically and internationally. Teligene aims to create original anti-tumor drugs with independent intellectual property rights, addressing emerging areas of research and development in the pharmaceutical field.

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the research, development, production, and commercialization of biologics, particularly monoclonal antibody (mAb) biosimilars and novel therapies. Founded in 2010, the company focuses on oncology and autoimmune diseases, offering products such as HLX01, a biosimilar for treating non-Hodgkin lymphoma. Henlius is actively advancing its pipeline, with multiple products under review for regulatory approval, alongside conducting numerous clinical studies for various therapies. The company collaborates with partners, including agreements to develop treatments for COVID-19 and eye diseases. Shanghai Henlius Biotech is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals, established in 2009, and operates out of the Shanghai Caohejing High-Technology Park.

The #1 international kindergarten in Beijing

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Leading financial and insurance technology company in China

Gaosi Education Group is a Chinese educational institution specializing in extracurricular tutoring for middle and primary school students. Founded in December 2009, it is headquartered in Beijing's Haidian District. The group focuses on gifted education, offering tailored courses for students from primary through junior high school. It features personalized one-on-one teaching centers and emphasizes mathematics competitions as a key component of its curriculum. With nearly 10,000 students enrolled, Gaosi Education Group employs around 100 full-time teachers and staff dedicated to teaching and research.

Linklogis Inc is a technology solution provider specializing in supply chain finance in China. The company develops a financial service platform that leverages big data, artificial intelligence, and blockchain technologies to facilitate direct connections between asset providers and funding sources. This enables small-sized companies to access financing more conveniently. Linklogis operates in two primary segments: Supply Chain Finance Technology Solutions and Emerging Solutions. The Supply Chain Finance Technology Solutions encompass products like Anchor Cloud and FI Cloud, while Emerging Solutions include offerings such as Crossborder Cloud and SME credit technology solutions. By focusing on practical applications and innovative technologies, Linklogis aims to enhance the efficiency of supply chain financial services in the market.

Pipilu is a company dedicated to providing entertainment content and products specifically designed for children in China. It focuses on producing original publishing materials, movies, animations, and various consumer products. By prioritizing quality in its offerings, Pipilu aims to deliver engaging and entertaining experiences that cater to the interests and needs of young audiences.

Established in 2013, Studio 9 is a leading original animation IP creation company. It has the highest-yield production line of comics and 2D & 3D animation in China. The company has built its IP production committee to further expand the value of its IP in animation, movies and games. It has also successfully created China's first action animation IP " The Outcast ", and hot IPs such as “No”, “Heaven to Earth”, etc.

Beijing Haixue Education Technology Co., Ltd. operates the Haixue platform, which provides employment and career development solutions tailored for students and professionals in China. The platform utilizes advanced technology, including artificial intelligence and big data analysis, to create personalized learning experiences and recommend relevant knowledge points. Haixue offers a range of skill training programs across various fields, such as construction, accounting, law, and health. By incorporating live lectures and high-definition broadcasting into its training system, the company enhances the learning experience and maximizes the workplace value of its users. Through its innovative approach, Haixue aims to facilitate hassle-free learning and professional development.

iDreamSky Technology, established in 2009 and headquartered in Shenzhen, China, is a leading digital entertainment platform in the Chinese game publishing market. It specializes in publishing third-party licensed and self-developed games, spanning genres like role-playing, puzzle, and casual competition, to players through various mobile channels and other publishers. As of 2019, its portfolio comprised 60 games. Additionally, iDreamSky offers digital content services, advertising, and other information services. It has collaborated with major clients such as Lenovo, China Telecom, and HTC. In 2011, it launched Skynet, a one-stop solution for game developers to expand and establish their businesses in China, following a seed investment of $2 million from Hwa Xiu Investment Group.

Luogic Thinking is China’s #1 online producer of educational podcasts.

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in Shanghai, China, focusing on the discovery, development, and commercialization of innovative drugs. The company operates in various therapeutic areas, including oncology, metabolic disorders, autoimmune diseases, and neurologic conditions. Junshi's notable products include JS001, a recombinant humanized anti-PD-1 monoclonal antibody marketed as TUOYIR for several cancers, and UBP1211, a biosimilar of Humira currently in Phase I clinical trials for rheumatoid arthritis and related conditions. Additionally, the company is advancing other drug candidates, such as JS002, a monoclonal antibody for hyperlipidemia, and several others in early-phase trials targeting various diseases. Junshi has established collaborations with leading pharmaceutical companies, including Eli Lilly and Merck, to develop therapeutic antibodies and explore new treatment combinations. Founded in 2012, Shanghai Junshi Biosciences is committed to addressing unmet medical needs through its extensive research and development initiatives.

China Mercy Health Group, founded by Liu Xiaocheng, focuses on enhancing the operational efficiency of medical institutions in China. Originating from the TEDA International Cardiovascular Hospital, which is recognized as a top-tier cardiovascular facility, the group offers a comprehensive range of services. These include hospital architecture and design, management consultancy, training for hospital staff, and procurement and logistics for medical devices and drugs. By providing these specialized services, China Mercy Health Group aims to create healthier environments for patients and improve the overall quality of healthcare in the region.

Wenzhou Kangning Hospital Co., Ltd., established in 1996 and headquartered in Wenzhou, China, operates a network of healthcare facilities specializing in psychiatric care. It offers a wide range of mental health services, including forensics, women's psychiatry, addiction treatment, geriatric psychiatry, and specialized clinics for depression, sleep disorders, and child & adolescent psychology. The company also provides teleconsultation services. In addition to its core medical services, Wenzhou Kangning Hospital engages in property development, leasing, and sale services, as well as software and information technology services.

Linklogis Inc is a technology solution provider specializing in supply chain finance in China. The company develops a financial service platform that leverages big data, artificial intelligence, and blockchain technologies to facilitate direct connections between asset providers and funding sources. This enables small-sized companies to access financing more conveniently. Linklogis operates in two primary segments: Supply Chain Finance Technology Solutions and Emerging Solutions. The Supply Chain Finance Technology Solutions encompass products like Anchor Cloud and FI Cloud, while Emerging Solutions include offerings such as Crossborder Cloud and SME credit technology solutions. By focusing on practical applications and innovative technologies, Linklogis aims to enhance the efficiency of supply chain financial services in the market.